{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:36:13Z","timestamp":1786628173003,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773281"],"award-info":[{"award-number":["81773281"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbrc.2026.154190","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:14:17Z","timestamp":1782404057000},"page":"154190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma"],"prefix":"10.1016","volume":"829","author":[{"given":"Wen","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154190_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154190_bib2","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1080\/21655979.2022.2031408","article-title":"microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3","volume":"13","author":"Li","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.bbrc.2026.154190_bib3","article-title":"Cancer statistics","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2026.154190_bib4","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154190_bib5","article-title":"Research progress of natural small-molecule compounds related to tumor differentiation","volume":"27","author":"He","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2026.154190_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","article-title":"Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells","volume":"18","author":"Ruf","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbrc.2026.154190_bib7","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.7150\/thno.25255","article-title":"Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics","volume":"8","author":"Zheng","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2026.154190_bib8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s13046-019-1444-0","article-title":"Upregulation of CENPM promotes hepatocarcinogenesis through multiple mechanisms","volume":"38","author":"Xiao","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154190_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-019-1128-9","article-title":"Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154190_bib10","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2026.154190_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","article-title":"Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection","volume":"81","author":"Fuster-Anglada","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154190_bib12","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.7150\/thno.72594","article-title":"Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2026.154190_bib13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bbrc.2026.154190_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154190_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbrc.2026.154190_bib16","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154190_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-Based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.154190_bib18","doi-asserted-by":"crossref","first-page":"eadd6997","DOI":"10.1126\/sciadv.add6997","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154190_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","article-title":"Natural killer cells at the frontline in the fight against cancer","volume":"15","author":"Coenon","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154190_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","article-title":"Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2026.154190_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/2326-6066.CIR-19-0483","article-title":"Inhibition of MICA and MICB shedding elicits NK-Cell-Mediated immunity against tumors resistant to cytotoxic T cells","volume":"8","author":"Ferrari de Andrade","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbrc.2026.154190_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrc.2026.154190_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216103","article-title":"Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia","volume":"558","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2026.154190_bib24","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.19.00177","article-title":"Immunotherapy of relapsed and refractory solid tumors with Ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study","volume":"37","author":"Hont","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154190_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12943-022-01669-8","article-title":"Tumor buster - where will the CAR-T cell therapy 'missile' go?","volume":"21","author":"Qu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2026.154190_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154190_bib27","article-title":"Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154190_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12967-025-06106-0","article-title":"Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression","volume":"23","author":"Zhou","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154190_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1583597","article-title":"Unveiling B7\/CD28 family proteins in hepatocellular carcinoma: insights into communication and prognostic significance","volume":"16","author":"Cai","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154190_bib30","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","article-title":"Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling","volume":"65","author":"Capurro","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154190_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154190_bib32","article-title":"Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154190_bib33","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.7150\/thno.49480","article-title":"Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2026.154190_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2018.00264","article-title":"B7H3 as a promoter of metastasis and promising therapeutic target","volume":"8","author":"Dong","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154190_bib35","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154190_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154190_bib37","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2026.154190_bib38","doi-asserted-by":"crossref","first-page":"9348","DOI":"10.7150\/thno.47677","article-title":"The C\/D box small nucleolar RNA SNORD52 regulated by Upf1 facilitates Hepatocarcinogenesis by stabilizing CDK1","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2026.154190_bib39","first-page":"665","article-title":"Targeting Glypican-3 for liver cancer therapy: clinical applications and detection methods","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154190_bib40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154190_bib41","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2600954X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2600954X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:58:14Z","timestamp":1786625894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2600954X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S0006291X2600954X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154190","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154190"}}